SB
EW icon

Strategic Blueprint’s Edwards Lifesciences EW Stock Holding History

Strategic Blueprint’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,935
Closed -$384K – 683
2025
Q3 		$384K Sell
4,935
-1,093
-18% -$85.4K 0.02% 540
2025
Q2 		$471K Buy
6,028
+2,397
+66% +$179K 0.02% 457
2025
Q1 		$263K Buy
3,631
+893
+33% +$63.9K 0.01% 572
2024
Q4 		$203K Buy
+2,738
New +$192K 0.01% 633
2022
Q2 		– Sell
-2,970
Closed -$350K – 511
2022
Q1 		$350K Buy
2,970
+442
+17% +$49.6K 0.04% 354
2021
Q4 		$328K Buy
2,528
+601
+31% +$70.1K 0.04% 361
2021
Q3 		$218K Sell
1,927
-1,469
-43% -$168K 0.03% 376
2021
Q2 		$352K Sell
3,396
-468
-12% -$44.1K 0.06% 283
2021
Q1 		$323K Buy
3,864
+130
+3% +$11K 0.07% 230
2020
Q4 		$341K Sell
3,734
-1,975
-35% -$164K 0.09% 175
2020
Q3 		$456K Buy
+5,709
New +$445K 0.14% 127
2019
Q4 		– Sell
-2,565
Closed -$188K – 194
2019
Q3 		$188K Buy
+2,565
New +$180K 0.14% 69

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Strategic Blueprint's EW Position: Q4 2025 in Review

Strategic Blueprint sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 4,935 shares — an estimated $384K sold.

Strategic Blueprint first reported a position in EW in Q3 2019 and held it in 12 quarters. The position peaked at $471K in Q2 2025. 1,314 funds tracked by Wall St. Rank hold EW as of Q4 2025.

  • Strategic Blueprint reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
  • Strategic Blueprint sold 4,935 Edwards Lifesciences shares in Q4 2025, an estimated $384K.
  • Strategic Blueprint first reported a position in Edwards Lifesciences in Q3 2019 and held it in 12 quarters.
  • Strategic Blueprint's Edwards Lifesciences position peaked at $471K in Q2 2025.
  • 1,314 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on Strategic Blueprint's 13F filing for Q4 2025, filed 30 Jan 2026.